Literature DB >> 4073075

Complications of diabetes. Prevalence, detection, current treatment, and prognosis.

R S Clements, D S Bell.   

Abstract

The late complications associated with diabetes mellitus affect the eye (retinopathy and cataract), the kidney (diabetic glomerulosclerosis), the nerves (mononeuropathies, distal symmetric polyneuropathy, and autonomic neuropathy), and the large blood vessels (coronary artery, cerebrovascular, and peripheral vascular disease). With the exception of large blood vessel disease, evidence in animals and humans has suggested that the development of diabetes-associated complications is related to metabolic abnormalities associated with hyperglycemia. Although the exact mechanism by which hyperglycemia causes damage in individual tissues is unknown, a number of potentially pathogenic mechanisms have been proposed. These include increased activity of the polyol pathway, disturbance in the metabolism of myo-inositol and its phospholipid derivatives, abnormal permeability of the small blood vessels, and excessive glycosylation of various proteins. With the introduction of potent aldose reductase inhibitors, the role of increased activity of the polyol pathway (and related abnormalities in myo-inositol metabolism) in the pathogenesis of diabetes-associated complications can be clarified.

Entities:  

Mesh:

Year:  1985        PMID: 4073075     DOI: 10.1016/0002-9343(85)90503-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Hyperglycemia is independently associated with post-operative function loss in patients with primary eloquent glioblastoma.

Authors:  Thomas W Link; Graeme F Woodworth; Kaisorn L Chaichana; Stuart A Grossman; Robert S Mayer; Henry Brem; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  J Clin Neurosci       Date:  2012-05-15       Impact factor: 1.961

Review 2.  Aldose reductase inhibitors and late complications of diabetes.

Authors:  P Benfield
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 3.  An update on the potential role of C-peptide in diabetes and osteoporosis.

Authors:  Arturo Pujia; Carmine Gazzaruso; Tiziana Montalcini
Journal:  Endocrine       Date:  2017-04-03       Impact factor: 3.633

4.  Survival outcomes for patients with surgically induced end-stage renal disease.

Authors:  Bimal Bhindi; Dennis Asante; Megan E Branda; LaTonya J Hickson; Ross J Mason; Molly M Jeffery; Stephen A Boorjian; Bradley C Leibovich; R Houston Thompson
Journal:  Can Urol Assoc J       Date:  2019-09-27       Impact factor: 1.862

5.  An endophytic Schizophyllum commune Fr. exhibits in-vitro and in-vivo antidiabetic activity in streptozotocin induced diabetic rats.

Authors:  Avinash Sharma; Rajvir Kaur; Jasleen Kaur; Saweta Garg; Rajbir Bhatti; Amarjeet Kaur
Journal:  AMB Express       Date:  2021-04-21       Impact factor: 3.298

Review 6.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

7.  Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.

Authors:  M Psallas; C Manes
Journal:  Hippokratia       Date:  2012-04       Impact factor: 0.471

8.  Exendin-4 improves resistance to Listeria monocytogenes infection in diabetic db/db mice.

Authors:  Hsien Yueh Liu; Chih-Yao Chung; Wen-Chin Yang; Chih-Lung Liang; Chi-Young Wang; Chih-Yu Chang; Cicero Lee-Tian Chang
Journal:  J Vet Sci       Date:  2012-09       Impact factor: 1.672

9.  Antidiabetic effect and mode of action of cytopiloyne.

Authors:  Cicero Lee-Tian Chang; Hsien-Yueh Liu; Tien-Fen Kuo; Yi-Jou Hsu; Ming-Yi Shen; Chien-Yuan Pan; Wen-Chin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-13       Impact factor: 2.629

10.  Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds.

Authors:  Cicero L T Chang; Yenshou Lin; Arlene P Bartolome; Yi-Ching Chen; Shao-Chih Chiu; Wen-Chin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-04       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.